Immix Biopharma financials
$10.54−8.11%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$30.0M | -$22.7M | -$16.1M | -$8.2M | -$1.4M |
| Net income | -$29.4M | -$21.6M | -$15.4M | -$8.2M | -$24.4M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-0.89 | $-0.76 | $-0.89 | $-0.59 | $-6.64 |
| EBITDA | -$29.7M | -$22.6M | -$16.1M | -$8.2M | -$1.3M |
| Operating cash flow | -$23.9M | -$14.6M | -$11.4M | -$7.4M | -$1.6M |
| Free cash flow | -$24.7M | -$15.8M | -$11.4M | -$7.4M | -$1.6M |
| Diluted shares | 33.0M | 28.3M | 17.3M | 13.9M | 3.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $93.9M | $17.7M | $17.5M | $13.4M | $17.6M |
| Short-term investments | $6.5M | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $59.1K |
| Total assets | $104.8M | $22.9M | $19.9M | $14.9M | $18.2M |
| Total liabilities | $11.0M | $9.7M | $3.7M | $1.7M | $202.0K |
| Shareholders' equity | $93.8M | $13.3M | $16.2M | $13.2M | $18.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology